Executive Committee (EC)

The EC consists of seven members: the President, the President Elect or the Past President, the Secretary, the Treasurer, and three additional members. All members of the EC, except the President and the Past President, are elected by secret ballot by the Council during a meeting of the Council. After a term of one year, the President Elect will automatically become President.

The members of the EC are not delegates of their respective countries. All details about the election process can be found in the statutes of the EFMC.

Previous composition of the EC can be found here

University of Lisbon, Portugal

Rui Moreira completed his Master degree at the Faculty of Pharmacy, University of Lisbon, and obtained his PhD under supervision of Professors Eduarda Rosa (University of Lisbon) and Jim Iley (The Open University). After a postdoctoral stay in the UK, Rui started his career as an independent scientist in Lisbon in 1993 and was promoted to Professor of Medicinal Chemistry in 2006, becoming Head of Department in 2010-2016, and Director of the Research Institute for Medicines (iMed.ULisboa) in 2010-2013.

Rui has wide research interests in the fields of Medicinal and Physical Organic Chemistry, covering the development of anti-infectious and anticancer agents, prodrug chemistry, structure-reactivity-metabolism relationships, design of covalent inhibitors, and design of chemical probes for activity- and photoaffinity-based protein profiling. He has published over 160 papers (Researcher ID G-7485-2011 and ORCID ID 0000-0003-0727-9852) and supervised/co-supervised more than 20 PhD students.

Rui was co-founder of the Medicinal Chemistry Division of the Portuguese Chemical Society, and as served EFMC as Council member in 2008-2015 and as Executive Committee member since 2015. He is the current EFMC President.

Novartis, Switzerland

Yves P. Auberson obtained his Ph.D. in 1990 at the Swiss Federal Institute of Technology in Lausanne, Switzerland. He joined the Novartis Institute for BioMedical Research in Basel, Switzerland in 1992, after a post-doctoral training in chemical biology at Affymax in Palo Alto, USA.

He is currently Executive Director in Global Discovery Chemistry, where his research group develops tracers for clinical imaging. Previously, he was Head of Chemistry for Neuroscience, and played a leading role in the discovery and development of drug candidates for the treatment of epilepsy, Alzheimer’s disease and narcolepsy.

He is President of the European Federation of Medicinal Chemistry (EFMC), and of the Division of Medicinal Chemistry and Chemical Biology of the Swiss Chemical Society.

Uppsala University, Sweden

Anders Karlén specializes in the field of computational medicinal chemistry and focuses on hit identification and lead development in drug discovery. His group works closely with synthetic medicinal chemists on targets of importance in infectious diseases with a focus on Tuberculosis, Malaria and gram-negative infections. Several of these projects have been run within EU framework 6 and 7 programmes.

He is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the €85 million, 6 year, Innovative Medicines Initiative (IMI) project ENABLE (European Gram Negative Antibacterial Engine).


Welab, Spain

Antoni Torrens studied Pharmaceutical Sciences at theUniversityofBarcelona, and got his PhD in Organic Chemistry in 1990, working in total synthesis of indole alkaloids under the supervision of Professor Joan Bosch. Then he joined Laboratorios Esteve as a medicinal chemist in theResearchCenterfor Drug Discovery.

After working as Project Leader for several years, in 2002 he was promoted to Head of Discovery Chemistry, and in 2006 he was appointed to Director of R&D Chemistry. Currently he is Responsible of External Collaborations and Strategic Alliances at Esteve Pharmaceuticals. From August 2020 he is working for WeLab a bioincubator platform created by ESTEVE and LEITAT.

During his career, he has directly contributed to the progress of several research projects in different therapeutic areas, which led to 6 new chemical entities that reached clinical development. Two of them are nowadays in Phase II and Phase III clinical trials.

He is an active participant teacher in Master and Doctorate Courses at several universities in Spain and Portugal and in several European Medicinal Chemistry Summer Schools.

He is member of the Spanish Society of Medicinal Chemistry (SEQT). After six years serving as a member of the Board, from 2011 to 2015 he was elected as President of the SEQT. In 2016 he was also elected as a member of the Executive Committee of the European Federation for Medicinal Chemistry (EFMC). From January 2019 he is serving as EFMC Treasurer.

University of Bonn, Germany

Christa E. Müller completed her PhD studies at the University of Tübingen, Germany, in the field of Pharmaceutical/Medicinal Chemistry in 1988 followed by a postdoctoral stay at the National Institutes of Health in Bethesda, Maryland, USA. After her return to Tübingen she completed her habilitation (post-doctorate degree) and became Associate Professor of Pharmaceutical Chemistry at the University of Würzburg, Germany, in 1994. Since 1998 she holds a Full Professorship at the University of Bonn, Germany. From 2001-2004 and from 2010-2015 she served as a Vice-Rector of Bonn University.

Prof. Müller is Editor-in-Chief for ACS Pharmacology & Translational Science (American Chemical Society) and a member of several Scientific and Editorial Boards. She has published nearly 500 scientific papers and received a number of awards for her work including the Nauta Award for Medicinal Chemistry and Chemical Biology of the EFMC.

Her main interest is in medicinal chemistry and molecular pharmacology of purine binding membrane proteins (adenosine receptors, P2 purine receptors, adenine receptors and ecto-nucleotidases) as well as lipid-activated and orphan G protein-coupled receptors. Recently she has embarked on the development of coronavirus inhibitors.

University of Salerno, Italy

Gianluca Sbardella graduated in Pharmaceutical Chemistry and Technology at the University of Rome ''La Sapienza'' (Italy) in 1993 and received his Ph.D. from the same University in 1997. In 2001 he joined the Department of Pharmacy of the University of Salerno, where since 2016 he is Full Professor in Medicinal Chemistry.

During his career, Gianluca was Research Fellow at the Drug Chemistry Center of CNR (Italian National Research Center) in 1997, Research Fellow at the Istituto Superiore di Sanità (ISS) - Italian National Institute of Health in 1998-1999, postdoctoral fellow at the University of Rome ''La Sapienza'' in 2000, Italy, and research associate at the University of Siena, Italy, in 2000-2001.

In 2004 he spent a sabbatical period as visiting professor at the Department of Chemistry & Biochemistry of the University of California, Los Angeles (UCLA). In 1994 and 1998 Gianluca was awarded with the Italian Pasteur Institute “Istituto Pasteur-Fondazione Cenci Bolognetti” Award. In 1995 he was awarded with the Italian Federation of Chemical Industry (Federchimica) Award. In 2008 Gianluca was awarded with the Farmindustria Italian National Award for Research Excellence in Medicinal Chemistry. In 2019 he received the Golden Seal of the Italian Chemical Society (società Chimica Italiana).

After an early interest in the discovery of antiviral drugs, his research currently regards most aspects of epigenetic drug discovery, spanning synthetic strategies, medicinal chemistry, chemical biology, biophysical techniques.

He is Author of over 110 papers on high-impact international MedChem journals, 3 book chapters, 3 patents (PCT) and over 120 communications in international congresses, comprising 30 invited lectures.

He is Vice Rector for International Relations, Coordinator of the PhD program in Drug Discovery and Development, and member of the Intellectual Property and Technology Transfer Commission of the University of Salerno.

From May 2017 he is the National Representative for Italy in the Innovative Medicine Initiative (IMI).

He is currently the President of the Medicinal Chemistry Division of the Italian Chemical Society (Divisione di Chimica Farmaceutica della Società Chimica Italiana)

SCT & Symeres, The Netherlands

Dr Van Hijfte holds a PhD degree in Chemistry from Gent University (1984, Belgium) with Prof M Vandewalle, and finalized his academic training by a two-year post-doctoral stay at UCSB with Prof RD Little. He started his industrial career as a medicinal chemist at Merrell Dow in 1986 in Strasbourg, France, where he progressed to head of the medicinal chemistry by the time the site had become part of Sanofi in 1998. In 2002 he moved to Janssen, J&J, first as Research Director of their R&D site in Val de Reuil, France, before taking on the role of Senior Director, Head of Medicinal Chemistry EU, at Janssen Research & Development, with responsibility for European-based medicinal chemistry, analytical technologies, and ADMET.

During this tenure, Luc was privileged to contribute to several successful projects, with numerous programs entering into clinical development in the areas of neurosciences, oncology, and infectious diseases. In 2012 Dr Van Hijfte became CSO of NovAliX, Illkirch, France, before moving in 2017 to his actual position of Sr VP Medicinal Chemistry at Mercachem-Syncom, where he oversees a team of approx. 80 chemists executing medicinal chemistry activities for clients worldwide.

Dr Van Hijfte has been the Vice-President of the French Medicinal Chemistry Society (SCT) in 2015-16, President of the SCT 2017-18, and is currently member of the Executive Committee of the EFMC. In 2018, he has been elected and named member of the “Académie Nationale de Pharmacie” in France, for his multiple contributions to pharmaceutical developments.